This site is intended for US healthcare professionals.
HEARING PROTECTION
Shouldn’t come with logistical noise
Support for access, logistics, and in-home infusion—so your team can stay focused on care, and your patients can stay focused on treatment.
Every dose of PEDMARK is backed by Fennec HEARS™, a comprehensive support system specially designed to remove access barriers, minimize treatment disruption, and help clinics and families navigate care—from start to finish. Whether in-clinic or at home, we make sure care doesn’t come with a caveat.
Program features include:
- Insurance-Related Support: Benefit verification, prior authorization, and appeals to ease access
- Patient Assistance Program: Options for eligible patients, including no-cost PEDMARK based on physician decision
- Quick Start Program: For patients facing delays in coverage, to help ensure timely treatment initiation
- Bridge Program: Assistance during insurance gaps to avoid missed doses or therapy disruption
- In-Home Nursing Support: PEDMARK can be administered by licensed nurses—bringing treatment directly to patients
One contact. Total support.
A dedicated Fennec HEARS™ Case Manager oversees every detail—so families, providers, and clinics have a single, steady point of support from start to finish.
Seamless, nationwide, at-home infusion
Our specialty pharmacy partner delivers home infusion therapy with:
- 50-state licensure
- 96% coverage across insured lives
- 3,000+ infusion nurses
- 5,000+ infusion specialists
With Fennec HEARS™, nothing stands between them and hearing their win
No patient should miss out on care due to cost or complexity
To enroll your patient in the Fennec HEARS™ Copay Program, visit: https://www.pedmark-copay.com
For additional support, contact Fennec HEARS™ at:
855-615-7946, Monday–Friday, 8 AM–8 PM ET
A Fennec HEARS™ professional does not offer medical advice or replace discussions with a healthcare provider.
Fennec HEARS™ is not related to acquisition, purchasing or reimbursement. For information in those areas, please contact your institution’s billing department or Fennec representative.
IMPORTANT SAFETY INFORMATION
- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
- Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
- PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.
- Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
- Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73 m2.
- Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.
- The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
Please see full Prescribing Information for PEDMARK.
INDICATIONS AND USAGE
PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non‑metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.